These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27729803)

  • 1. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
    Abedin SM; Boddy CS; Munshi HG
    Onco Targets Ther; 2016; 9():5943-5953. PubMed ID: 27729803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BET bromodomain proteins in solid tumors.
    Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
    Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
    Chaidos A; Caputo V; Karadimitris A
    Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors.
    Wadhwa E; Nicolaides T
    Cureus; 2016 May; 8(5):e620. PubMed ID: 27382528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].
    Gao RL; Zeng CW; Li YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1365-1368. PubMed ID: 34362532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations.
    Ma T; Chen Y; Yi ZG; Li YH; Bai J; Li LJ; Zhang LS
    Genes Dis; 2023 Nov; 10(6):2306-2319. PubMed ID: 37554207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
    Reyes-Garau D; Ribeiro ML; Roué G
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31581671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
    Alqahtani A; Choucair K; Ashraf M; Hammouda DM; Alloghbi A; Khan T; Senzer N; Nemunaitis J
    Future Sci OA; 2019 Mar; 5(3):FSO372. PubMed ID: 30906568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies.
    Bertoni F; Stathis A
    Curr Opin Hematol; 2019 Jul; 26(4):273-280. PubMed ID: 31116107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
    Braun T; Gardin C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET inhibitors: a novel epigenetic approach.
    Doroshow DB; Eder JP; LoRusso PM
    Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain inhibitors: what does the future hold?
    Bhattacharya S; Piya S; Borthakur G
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Proteins as Targets for Anticancer Treatment.
    Stathis A; Bertoni F
    Cancer Discov; 2018 Jan; 8(1):24-36. PubMed ID: 29263030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics.
    Halder TG; Soldi R; Sharma S
    Curr Opin Oncol; 2021 Sep; 33(5):526-531. PubMed ID: 34280171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials.
    Sun Y; Han J; Wang Z; Li X; Sun Y; Hu Z
    Front Pharmacol; 2020; 11():621093. PubMed ID: 33574760
    [No Abstract]   [Full Text] [Related]  

  • 18. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
    Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
    Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET bromodomain inhibitors in leukemia.
    Basheer F; Huntly BJ
    Exp Hematol; 2015 Aug; 43(8):718-31. PubMed ID: 26163798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.